OncoCyte (OCX) 10-K 27 Feb 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Feb. 17, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	OncoCyte Corp
Entity Central Index Key	1,642,380
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 14.7
Entity Common Stock, Shares Outstanding		29,361,616
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 10,174	$ 7,996
BioTime shares held as available-for-sale securities, at fair value	2,237	2,541
Prepaid expenses and other current assets	285	388
Total current assets	12,696	10,925
NONCURRENT ASSETS
Intangible assets, net	988	1,230
Equipment and furniture, net	688	576
Deposits	75	0
TOTAL ASSETS	14,447	12,731
CURRENT LIABILITIES
Amount due to parent, BioTime	2,703	807
Amount due to affiliates	151	40
Accounts payable	422	285
Accrued expenses and other current liabilities	797	1,182
Capital lease liability	202	0
Total current liabilities	4,275	2,314
LONG-TERM LIABILITIES
Capital lease liability	310	0
TOTAL LIABILITIES	4,585	2,314
Commitments and contingencies (see Note 9)
STOCKHOLDERS' EQUITY
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	0	0
Common stock, no par value, 50,000 shares authorized; 28,737 and 25,391 shares issued and outstanding at December 31, 2016 and 2015, respectively	45,818	34,901
Accumulated other comprehensive loss on available-for-sale securities	(654)	(350)
Accumulated deficit	(35,302)	(24,134)
Total stockholders' equity	9,862	10,417
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 14,447	$ 12,731

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2016	Dec. 31, 2015
STOCKHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	5,000	5,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common shares, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares issued (in shares)	28,737	25,391
Common shares, shares outstanding (in shares)	28,737	25,391

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
OPERATING EXPENSES
Research and development	$ 5,677	$ 4,527	$ 3,962
General and administrative	5,463	4,191	1,011
Total operating expenses	11,140	8,718	4,973
Loss from operations	(11,140)	(8,718)	(4,973)
OTHER EXPENSES, NET
Interest expense, net	(28)	(19)	(2)
Other income (expenses), net	0	2	(11)
Total other expenses, net	(28)	(17)	(13)
NET LOSS	$ (11,168)	$ (8,735)	$ (4,986)
Basic and diluted net loss per share (in dollars per share)	$ (0.42)	$ (0.42)	$ (0.27)
Weighted average shares outstanding: basic and diluted (in shares)	26,529	21,009	18,200

STATEMENTS OF COMPREHENSIVE LOS

STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
STATEMENTS OF COMPREHENSIVE LOSS [Abstract]
NET LOSS	$ (11,168)	$ (8,735)	$ (4,986)
Other comprehensive loss, net of tax:
Realized loss on sale of BioTime shares	0	397	569
Unrealized (loss) gain on BioTime shares held as available-for-sale securities	(304)	75	(21)
COMPREHENSIVE LOSS	$ (11,472)	$ (8,263)	$ (4,438)

STATEMENTS OF STOCKHOLDERS' EQU

STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Total
BALANCE at Dec. 31, 2013	$ 15,398	$ (1,370)	$ (10,413)	$ 3,615
BALANCE (in shares) at Dec. 31, 2013	18,200
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	(4,986)	(4,986)
Unrealized gain (loss) on BioTime shares held as available-for-sale securities	0	(21)	0	(21)
Stock-based compensation	318	0	0	318
Common stock issued to BioTime for extinguishment of debt				0
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest				0
Transfer of realized loss into equity from sale of BioTime shares	(569)	569	0	0
BALANCE at Dec. 31, 2014	$ 15,147	(822)	(15,399)	(1,074)
BALANCE (in shares) at Dec. 31, 2014	18,200
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	(8,735)	(8,735)
Unrealized gain (loss) on BioTime shares held as available-for-sale securities	0	75	0	75
Stock-based compensation	$ 1,815	0	0	1,815
Common stock issued to BioTime for extinguishment of debt (in shares)	1,500
Common stock issued to BioTime for extinguishment of debt	$ 3,300	0	0	3,300
Common stock issued to investors for cash (in shares)	1,500
Common stock issued to investors for cash	$ 3,300	0	0	3,300
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest (in shares)	1,508
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest	$ 3,318	0	0	3,318
Common stock issued to BioTime for cash (in shares)	2,711
Common stock issued to BioTime for cash	$ 8,349	0	0	8,349
Exercise of stock options (in shares)	3
Exercise of stock options	$ 4	0	0	4
Fair value of contingently issuable warrant	$ 65	0	0	65
OncoCyte common stock received as a dividend in kind from BioTime (in shares)	(31)
OncoCyte common stock received as a dividend in kind from BioTime	$ 0	0	0	0
Transfer of realized loss into equity from sale of BioTime shares	(397)	397	0	0
BALANCE at Dec. 31, 2015	$ 34,901	(350)	(24,134)	$ 10,417
BALANCE (in shares) at Dec. 31, 2015	25,391			25,391
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	(11,168)	$ (11,168)
Unrealized gain (loss) on BioTime shares held as available-for-sale securities	0	(304)	0	(304)
Stock-based compensation	$ 922	0	0	922
Common stock issued to BioTime for extinguishment of debt				0
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest				0
Proceeds from issuance of common stock and warrants, net of discounts and financing costs (in shares)	3,246
Proceeds from issuance of common stock and warrants, net of discounts and financing costs	$ 9,777			9,777
Exercise of stock options (in shares)	100
Exercise of stock options	$ 218	0	0	218
BALANCE at Dec. 31, 2016	$ 45,818	$ (654)	$ (35,302)	$ 9,862
BALANCE (in shares) at Dec. 31, 2016	28,737			28,737

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,168)	$ (8,735)	$ (4,986)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	145	41	39
Amortization of intangible assets	242	242	242
Stock-based compensation	922	1,815	318
Contingently issuable warrant expense to investors	0	65	0
Interest expense	0	18	0
Changes in operating assets and liabilities:
Amount due to parent, BioTime	1,896	1,672	2,823
Amount due to affiliates	111	(115)	103
Prepaid expenses and other current assets	101	(274)	6
Accounts payable and accrued liabilities	229	1,042	291
Net cash used in operating activities	(7,522)	(4,229)	(1,164)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(106)	(500)	(9)
Proceeds from sale of BioTime shares	0	815	1,329
Security deposit	(75)	0	0
Net cash provided by (used in) investing activities	(181)	315	1,320
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of options	218	4	0
Proceeds from sale of common stock	0	11,649	0
Proceeds from sale of common stock and warrants	10,550	0	0
Financing costs related to sale of common stock and warrants	(773)	0	0
Repayment of capital lease obligation	(114)	0	0
Net cash provided by financing activities	9,881	11,653	0
NET INCREASE IN CASH AND CASH EQUIVALENTS	2,178	7,739	156
CASH AND CASH EQUIVALENTS:
At beginning of the year	7,996	257	101
At end of the year	10,174	7,996	257
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES
Equipment purchased under capital leases	626	0	0
Common stock issued to BioTime for extinguishment of debt	0	3,300	0
Common stock issued to BioTime upon conversion of convertible note payable and accrued interest	0	3,318	0
Realized loss on sale of BioTime shares	$ 0	$ 397	$ 569

Organization, Description of th

Organization, Description of the Business and Liquidity	12 Months Ended
	Dec. 31, 2016
Organization, Description of the Business and Liquidity [Abstract]
Organization, Description of the Business and Liquidity	1. Organization, Description of the Business and Liquidity OncoCyte Corporation (“OncoCyte”) was incorporated in 2009 in the state of California and at December 31, 2016 was a majority-owned subsidiary of BioTime, Inc. (“BioTime”), a publicly traded biotechnology company focused in the field of regenerative medicine. As discussed in Note 10, effective February 17, 2017, OncoCyte ceased to be a subsidiary of BioTime for financial reporting purposes when BioTime’s percentage ownership of outstanding OncoCyte common stock declined below 50% as a result of the issuance of additional OncoCyte common stock to certain investors who exercised OncoCyte stock purchase warrants. OncoCyte is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers broadly expressed in numerous types of cancer. OncoCyte is presently focusing its efforts on developing diagnostic tests for use in detecting a variety of cancers including lung, bladder, and breast cancers. Liquidity For all periods presented, OncoCyte had generated no revenues. Since inception, OncoCyte has financed its operations through the sale of its common stock and warrants to its shareholders, including BioTime, loans from BioTime and other BioTime affiliates, warrant exercises, and a bank loan (see Note 10), and sales of BioTime common shares that OncoCyte held as available-for-sale securities (see Note 2). OncoCyte has incurred operating losses and negative cash flows since inception, and had an accumulated deficit of $35.3 million and $24.1 million as December 31, 2016 and 2015, respectively. OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte’s research and development efforts are successful to the point where it believes that a commercial product can be launched successfully, then additional capital will be required for developing a sales and marketing team and launching OncoCyte’s first diagnostic test. Dependent on results of any product commercialization and ongoing sales, if any, additional capital might be required in 2017 or beyond to develop and launch products, for working capital, and for other expenses. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all. At December 31, 2016, we had $10.2 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $2.2 million. On February 17, 2017, OncoCyte received cash proceeds of $2.0 million when certain investors exercised 625,000 warrants to purchase OncoCyte common stock at an exercise price of $3.25 per share. The warrants had been issued as part of a financing that was completed on August 29, 2016, through which OncoCyte sold an aggregate of 3,246,153 immediately separable “units”, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (see Note 10). On February 21, 2017, OncoCyte entered into a Loan and Security Agreement with Silicon Valley Bank for a working capital loan of $2 million, collateralized by substantially all of OncoCyte’s assets other than intellectual property such as patents and trade secrets that OncoCyte owns (see Note 10). Based on cash and cash equivalents currently on hand, including the warrant exercises and working capital loan under the Loan Agreement discussed above and in Note 10, OncoCyte believes it has sufficient cash, cash equivalents, available for sale securities and working capital to carry out its current operations through at least twelve months from the issuance date of the financial statements included herein (see Note 2).

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The financial statements presented herein have been prepared on a separate, stand-alone basis. The financial statements are presented in accordance with U.S. generally accepted accounting principles (“GAAP”). BioTime has consolidated the results of OncoCyte into BioTime’s consolidated results based on BioTime’s ability to control OncoCyte’s operating and financial decisions and policies through its majority ownership of OncoCyte common stock throughout the periods presented. BioTime owned 51.1% and 57.7% of the outstanding common stock of OncoCyte at December 31, 2016 and 2015, respectively. As more fully discussed in Note 10, on February 17, 2017, BioTime’s percentage ownership of the outstanding OncoCyte common stock declined below 50%, resulting in a loss of “control,” of OncoCyte as under GAAP and a result, BioTime deconsolidated OncoCyte’s financial statements from BioTime’s consolidated financial statements. As a result of this deconsolidation, OncoCyte is no longer considered a subsidiary of BioTime under GAAP as of February 17, 2017. OncoCyte remains an affiliate of BioTime based on BioTime’s retained share ownership in OncoCyte which is sufficient to allow BioTime to exert significant influence over the operations and management of OncoCyte. To the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to OncoCyte’s operations or management. Management evaluates the appropriateness of the percentage allocations on a quarterly basis and believes that this basis for allocation is reasonable. As further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of operations for the services performed in the periods presented. Reverse stock split On November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes, where applicable, to reflect the impact of the reverse stock split. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including those related to going concern assessment of OncoCyte financial statements, the allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates. Going concern assessment With the implementation of FASB’s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte will assess going concern uncertainty in its financial statements to determine if it has sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the “look-forward period” as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15. Fair value measurements OncoCyte accounts for fair value measurements in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements · Level 1 · Level 2 · Level 3 In determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items. Cash and cash equivalents Cash equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December 31, 2016 and 2015, OncoCyte's cash balances totaled $10.2 million and $8.0 million, respectively, and consist of bank account deposits and $9.4 million held in money market funds at December 31, 2016. Financial instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies. OncoCyte places its cash and cash equivalents with high credit quality financial institutions. Accounting for BioTime shares OncoCyte accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25, Investments – Debt and Equity Securities As discussed in Note 10, on February 17, 2017, as a result of a loss of control experienced by BioTime on OncoCyte due to BioTime’s reduced ownership to below 50% of OncoCyte outstanding common stock, BioTime deconsolidated OncoCyte’s financial statements from BioTime’s consolidated financial statements. Due to this deconsolidation and BioTime no longer having a controlling financial interest in OncoCyte’s operations and financial statements, any realized gains and losses OncoCyte generates from the sale of BioTime shares, beginning on February 17, 2017, will be included in OncoCyte’s statements of operations. As of December 31, 2016, OncoCyte held 619,706 BioTime common shares as available-for-sale securities with a fair market value of $2.2 million. Long-lived intangible assets Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years. Equipment and furniture Equipment and furniture are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under capital leases, OncoCyte depreciates the equipment based on the lower of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the capital lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in OncoCyte’s results of operations. Impairment of long-lived assets OncoCyte assesses the impairment of long-lived assets, which consist primarily of long-lived intangible assets, furniture and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset’s carrying value over its fair value is recorded. Through 2016, there have been no such impairment losses. Accounting for warrants OncoCyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity , then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock . Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate OncoCyte to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, OncoCyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, OncoCyte also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, OncoCyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require to be accounted for at fair value at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. OncoCyte does not have any liability classified warrants as of any period presented. See Note 6. Income taxes OncoCyte has filed a standalone U.S. federal income tax return since its inception. For California purposes, OncoCyte’s activity for 2015 and 2016 has been or will be included in BioTime’s California combined tax return. The provision for income taxes has been determined as if OncoCyte had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by OncoCyte, will remain with OncoCyte. OncoCyte accounts for income taxes in accordance with ASC 740, Income Taxes The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. OncoCyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2016 and 2015. OncoCyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2016 and 2015. OncoCyte is currently unaware of any tax issues under review. Research and development expenses Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, and expenses for outside consultants. These expenses include both direct and allocated or indirect overhead costs allocated by BioTime (see Note 4). Research and development costs are expensed as incurred. General and administrative expenses OncoCyte’s general and administrative expenses relate primarily to compensation and related benefits, including stock-based compensation, for executive and corporate personnel, including direct costs and costs allocated by BioTime; professional and consulting fees; direct overhead and indirect overhead allocated by BioTime (see Note 4). Stock-based compensation OncoCyte recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718, Compensation – Stock Compensation OncoCyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures, over the requisite service period. OncoCyte uses the Black-Scholes option pricing model for estimating the fair value of options granted under OncoCyte’s Stock Option Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. OncoCyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis, net of estimated forfeitures, over the requisite service period. Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718 and FASB ASC 505-50, Equity-Based Payments to Non-Employees The Black-Scholes option pricing model requires OncoCyte to make certain assumptions including the fair value of the underlying common stock, the expected option term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 7). The fair value of the shares of common stock underlying the stock options has historically been determined by the Board of Directors. Because there was no public market for OncoCyte’s common stock prior to December 31, 2015, the Board of Directors determined the fair value of the common stock at the time of the grant of options by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, among other factors in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled Valuation of Privately Held Company Equity Securities Issued As Compensation The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. OncoCyte estimates the expected term of options granted based upon the “simplified method” provided under Staff Accounting Bulletin, Topic 14 Because OncoCyte’s common stock had no public trading history prior to December 31, 2015, for the years ended December 31, 2015 and 2014, OncoCyte estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to OncoCyte, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the year ended December 31, 2016, OncoCyte estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of stock of peer companies. OncoCyte determined the expected volatility assumption using the frequency of daily historical prices of comparable public company’s common stock for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of OncoCyte’s stock options. The dividend yield assumption is based on OncoCyte’s history and expectation of dividend payouts. OncoCyte has never declared or paid any cash dividends on its common stock, and OncoCyte does not anticipate paying any cash dividends in the foreseeable future. Net loss per common share Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the weighted-average number of shares of common stock outstanding plus the potential effect of dilutive securities or contracts which are convertible to common stock, such as stock options (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Because OncoCyte reported net losses for all periods presented, all potentially dilutive common stock are antidilutive for those periods. The computations of basic and diluted net loss per common share for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands, except per share amounts): 2016 2015 2014 Net loss $ (11,168 ) $ (8,735 ) $ (4,986 ) Weighted average common shares outstanding – basic and diluted 26,529 21,009 18,200 Net loss per common share – basic and diluted $ (0.42 ) $ (0.42 ) $ (0.27 ) The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2016, 2015 and 2014 because including them would have been antidilutive (in thousands): 2016 2015 2014 Stock options under Stock Option Plan 3,017 2,240 1,361 Warrants 3,246 - - Segments OncoCyte’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, OncoCyte’s executive management team has viewed OncoCyte’s operations as one segment that includes, the research and development of diagnostic tests for the detection of cancer. As a result, the financial information disclosed materially represents all of the financial information related to OncoCyte’s sole operating segment. Recent accounting pronouncements The following accounting standards, which are not yet effective, are presently being evaluated by OncoCyte to determine the impact that they might have on its financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). In April 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing”. The amendments clarify two aspects of Topic 606: (a) identifying performance obligations; and (b) the licensing implementation guidance. The update is effective for annual periods beginning after December 15, 2017 including interim reporting periods therein. OncoCyte does not expect the adoption of ASC 606 will have a material impact on its financial statements. On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” (ASU No. 2016-01). Changes to the current GAAP model primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU No. 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU No. 2016-01, when adopted, could have a material impact to OncoCyte’s financial statements based on the current accounting for shares of BioTime common stock OncoCyte holds as available-for-sale securities. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those annual periods. Early adoption is permitted. OncoCyte is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements. In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The update is effective for fiscal years beginning after December 15, 2016. OncoCyte is currently evaluating the impact the adoption of ASU 2016-09 will have on its financial statements.

Selected Balance Sheet Componen

Selected Balance Sheet Components	12 Months Ended
	Dec. 31, 2016
Selected Balance Sheet Components [Abstract]
Selected Balance Sheet Components	3. Selected Balance Sheet Components Prepaid expenses and other current assets At December 31, 2016 and 2015, prepaid expenses and other current assets were comprised of the following (in thousands): 2016 2015 Outside research $ - $ 366 Insurance 182 - Other prepaid expenses and current asset 103 22 Prepaid expenses and other current assets $ 285 $ 388 Accrued expenses and other current liabilities At December 31, 2016 and 2015, accrued expenses and other current liabilities were comprised of the following (in thousands): 2016 2015 Accrued bonuses and payroll related expenses $ 549 $ 325 Other accrued expenses 248 857 Accrued expenses and other current liabilities $ 797 $ 1,182 Intangible assets, net In 2011, OncoCyte, through its then parent, BioTime, acquired substantially all of the assets of Cell Targeting, Inc., a company that was engaged in cancer therapy. The assets acquired consist primarily of patents, patent applications, and licenses to use certain patents. OncoCyte amortizes intangible assets over their useful lives estimated to be 10 years at the date of the acquisition. At December 31, 2016 and 2015, intangible assets were comprised of the following (in thousands): 2016 2015 Intangible assets $ 2,419 $ 2,419 Accumulated amortization (1,431 ) (1,189 ) Intangible assets, net $ 988 $ 1,230 Amortization expense amounted to approximately $242,000 annually. Equipment and furniture, net At December 31, 2016 and 2015, equipment and furniture were comprised of the following (in thousands): 2016 2015 Equipment and furniture $ 1,007 $ 750 Accumulated depreciation (319 ) (174 ) Equipment and furniture, net $ 688 $ 576 Depreciation expense amounted to approximately $145,000, $41,000 and $39,000 for the years ended December 31, 2016, 2015 and 2014, respectively. During the year ended December 31, 2016, OncoCyte entered into capital leases for laboratory equipment totaling $626,000.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions Shared Facilities and Service Agreement On October 8, 2009, OncoCyte and BioTime executed a Shared Facilities and Services Agreement (“Shared Facilities Agreement”). Under the terms of the Shared Facilities Agreement, BioTime will allow OncoCyte to use its premises and equipment located at Alameda, California for the sole purpose of conducting business. BioTime will also provide accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte. BioTime may also provide the services of attorneys, accountants, and other professionals who may also provide professional services to BioTime and its other subsidiaries. BioTime will also provide OncoCyte with the services of its laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte at the premises. BioTime charges OncoCyte a Use Fee for services received and usage of facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates costs incurred, as applicable, to OncoCyte, such costs include services of Bio Time employees, equipment, insurance, lease, professional, software, supplies and utilities. Allocation depends on key cost drivers including actual documented use, square footage of facilities used, time spent, costs incurred by or for OncoCyte, or upon proportionate usage by BioTime and OncoCyte, as reasonably estimated by BioTime (collectively “Use Fees”). BioTime, at its discretion, has the right to charge OncoCyte a 5% markup on such allocated costs although BioTime has not elected to charge this markup since the inception of the Shared Facilities Agreement and through the end of 2015. Beginning in 2016, BioTime commenced charging the 5% markup. The allocated cost of BioTime employees and contractors who provide services is based upon records maintained of the number of hours of such personnel devoted to the performance of services. The Use Fee is determined and invoiced to OncoCyte on a quarterly basis for each calendar quarter of each calendar year. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by OncoCyte within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from OncoCyte funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of OncoCyte. Through December 31, 2016 BioTime has not charged OncoCyte any interest. In addition to the Use Fees, OncoCyte will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided that invoices documenting such costs are delivered to OncoCyte with each invoice for the Use Fee. Furthermore, BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte, and if any such supplies, goods, materials or services are obtained for OncoCyte, BioTime may arrange for the suppliers thereof to invoice OncoCyte directly. The Shared Facilities Agreement will remain in effect, unless either party gives the other party written notice stating that the Shared Facilities Agreement will terminate on December 31 of that year, or unless the agreement otherwise is terminated under another provision of the agreement. In the aggregate, BioTime allocated and charged such Use Fees to OncoCyte approximating $790,000, $595,000 and $344,000 included in general and administrative expenses, and $691,000, $565,000 and $552,000 included in research and development expenses included in the statements of operations during the years ended December 31, 2016, 2015 and 2014, respectively. As of December 31, 2016 and 2015, OncoCyte had $2.9 million and $847,000 outstanding and payable to BioTime and affiliates included in current liabilities in connection with the costs incurred under the Shared Facilities Agreement. Since these amounts are due and payable in 30 days of being invoiced, the payables are classified as current liabilities for all periods presented.

Related Party Convertible Promi

Related Party Convertible Promissory Note Payable	12 Months Ended
	Dec. 31, 2016
Related Party Convertible Promissory Note Payable [Abstract]
Related Party Convertible Promissory Note Payable	5. Related Party Convertible Promissory Note Payable In May 2015, OncoCyte entered into Subscription Agreements with BioTime and two other shareholders (see Note 6). In connection with the Subscription Agreements, BioTime purchased 1,500,000 shares of OncoCyte common stock in exchange for the cancellation of $3.3 million of indebtedness owed to BioTime by OncoCyte, and OncoCyte delivered to BioTime a convertible promissory note (the “Note”) for an additional $3.3 million of OncoCyte’s indebtedness to BioTime. The cancellation of the aggregate $6.6 million of indebtedness owed to BioTime was an extinguishment of debt under the provisions of ASC 470-50, Debt Modification and Extinguishment BioTime converted the Note into 1,508,095 shares of OncoCyte common stock during November 2015, and upon conversion the note balance and accrued interest was transferred to equity pursuant to ASC 470-20-40-5, Debt with Conversion and Other Options

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2016
Shareholders' Equity [Abstract]
Shareholders' Equity	6. Shareholders’ Equity Preferred Stock OncoCyte is authorized to issue up to 5,000,000 shares of no par value preferred stock. As of December 31, 2016, no preferred shares were issued or outstanding. Common Stock OncoCyte has up to 50,000,000 shares of no par value common stock authorized. The holders of OncoCyte’s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of OncoCyte common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of OncoCyte outstanding preferred shares, if any. The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of OncoCyte stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable. Issuance of Common Stock In May 2015, OncoCyte entered into Subscription Agreements with Bio Time and two other shareholders (“Investors”). Under the Subscription Agreements, OncoCyte issued 1,500,000 shares of common stock to the Investors for $3.3 million cash, or $2.20 per share. Concurrently, BioTime purchased 1,500,000 shares of OncoCyte common stock in exchange for the cancellation of $3.3 million of indebtedness owed to BioTime by OncoCyte (see Note 5). During September 2015, OncoCyte entered into a Subscription Agreement with BioTime pursuant to which BioTime purchased 2,710,857 shares of OncoCyte common stock for $8.3 million in cash, as part of a subscription offer made to all OncoCyte shareholders on a pro rata basis. On December 31, 2015, in connection with BioTime’s distribution of OncoCyte common stock to BioTime shareholders, on a pro rata basis, OncoCyte received 30,985 shares of its own common stock from BioTime as a dividend in kind. On that date, BioTime shareholders, including OncoCyte, received one share of OncoCyte common stock for every twenty shares of BioTime common stock held. The OncoCyte common stock distributed to OncoCyte was immediately retired on that date and reverted to the status of authorized but unissued common stock. Issuance of Common Stock and Warrants On August 29, 2016, OncoCyte sold an aggregate of 3,246,153 immediately separable units, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (the “Offering Warrants”), at a price of $3.25 per unit (the “Offering”). The sales were made pursuant to the terms and conditions of certain Purchase Agreements between OncoCyte and the purchasers in the Offering. The purchasers included certain OncoCyte existing shareholders other than BioTime. At the close of the Offering, BioTime’s percentage ownership of the outstanding common stock of OncoCyte declined to 51.2% through which BioTime retained a controlling interest in OncoCyte Pursuant to the terms of the Purchase Agreements, on September 26, 2016, OncoCyte filed a resale registration statement on Form S-1, referred to as the Resale Registration Statement, with the Securities and Exchange Commission, or SEC, to register for sale under the Securities Act of 1933, as amended, or the Securities Act, the shares of OncoCyte common stock sold in the Offering and the shares of OncoCyte common stock, or Warrant Shares, that may be issued if the Warrants are exercised. The SEC declared the Resale Registration Statement effective on October 20, 2016. OncoCyte has agreed to use commercially reasonable efforts to maintain the effectiveness of the Resale Registration Statement under the Securities Act until the earlier of (i) the date that all shares of its common stock covered by the Resale Registration Statement have been sold or can be sold publicly without restriction or limitation under Rule 144 (including, without limitation, the requirement to be in compliance with Rule 144(c)(1)), or (ii) August 29, 2018. OncoCyte was in compliance with the aforementioned terms of the Purchase Agreement as of the date of this report. Offering Warrants The Offering Warrants have an exercise price of $3.25 per Warrant Share, and may be exercised for five years from October 17, 2016, the date the Offering Warrants became exercisable. The Warrants may be exercised on a net “cashless exercise” basis, meaning that the value of a portion of Warrant Shares may be used to pay the exercise price (rather than payment in cash), in certain circumstances, including if the Resale Registration Statement is not effective when and as required by the Purchase Agreements. The exercise price and the number of Warrant Shares will be adjusted to account for certain transactions, including stock splits, dividends paid in common stock, combinations or reverse splits of common stock, or reclassifications of common stock. Under certain provisions of the OncoCyte Offering Warrants, in the event of a Fundamental Transaction, as defined in the Offering Warrants, OncoCyte will use reasonable best efforts for the acquirer, or any successor entity other than OncoCyte, to assume the Offering Warrants. If the acquirer does not assume the OncoCyte Offering Warrant obligations, then the acquirer shall pay the holders of Offering Warrants an amount equal to the aggregate value equal to the Black Scholes Value, as defined in the Offering Warrants. The payment of the Black Scholes Value shall be made in cash or such other consideration as the acquirer paid to the other OncoCyte shareholders in the Fundamental Transaction. OncoCyte is not required to net cash settle the Offering Warrants under any circumstance. Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock See Note 10 concerning the exercise of a portion of the Warrants on February 17, 2017 and the issuance of additional stock purchase warrants upon such exercise.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2016
Stock-based Compensation [Abstract]
Stock-based Compensation	7. Stock-based Compensation Stock Option Plan OncoCyte has adopted a 2010 Stock Option Plan (the “Plan”) under which OncoCyte initially authorized 2,000,000 shares of common stock for the grant of stock options or the sale of restricted stock. The Plan was amended to increase the authorized shares available for grant by 2,000,000 in 2015. The Plan also permits OncoCyte to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine. No options may be granted under the Plan more than ten years after the date upon which the Plan was adopted by the Board of Directors, and no options granted under the Plan may be exercised after the expiration of ten years from the date of grant. Under the Plan, options to purchase common stock may be granted to employees, directors and certain consultants at exercise prices not less than the fair market value of common stock at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee. Generally, OncoCyte stock options have service related vesting conditions based on the continued performance of services for OncoCyte. The Plan also permits OncoCyte to award restricted stock for services rendered or to sell common stock to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events. OncoCyte may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares. To date, only stock options have been issued under the Plan. As discussed in Note 4, in connection with the services performed by employees of BioTime, or employees of other BioTime subsidiaries, OncoCyte grants stock options to those employees performing services for OncoCyte and records stock-based compensation expense in the accompanying statements of operations for these services performed in the periods presented. Stock Options Options granted under the Plan may be either “incentive stock options” within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the “Code”), or non-qualified stock options. Incentive stock options may be granted only to OncoCyte employees and employees of its subsidiaries, if any. The exercise price of stock options granted under the Plan must be equal to the fair market value of OncoCyte common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of OncoCyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of OncoCyte common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $100,000. The options’ exercise price may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board of Directors or Compensation Committee may approve. Incentive stock options granted under the Plan are nontransferable except by will or the laws of descent and distribution and may be exercised only during employment or within three months after termination of such employment, subject to certain exceptions in the event of the death or disability of the optionee. Options other than incentive stock options under the Code are also nontransferable except by will or the laws of descent and distribution, except to the extent that the Board of Directors or Committee permits the optionee to transfer an option to a family member, a trust for family members, or other persons approved by the Board of Directors or Committee in its discretion. Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter as approved by the Board of Directors or Committee, but in the case of the termination of an employee, director, or consultant’s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option. The number of shares of common stock covered by the Plan, and the number of shares of common stock and the exercise price per share of each outstanding option, shall be proportionately adjusted for any increase or decrease in the number of issued and outstanding shares of common stock resulting from a subdivision or consolidation of shares or the payment of a stock dividend, or any other increase or decrease in the number of issued and outstanding shares of common stock effected without receipt of consideration by OncoCyte. Options Granted As of December 31, 2016, 880,417 shares were available for future grants under the Plan. A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price): Options Available for Grant Number of Options Outstanding Weighted Average Exercise Price Total at January 1, 2015 639 1,361 $ 1.52 Increase in option pool 2,000 - Options granted (1,448 ) 1,448 2.21 Options exercised - (3 ) 1.34 Options forfeited or cancelled 566 (566 ) 1.59 Total at December 31, 2015 1,757 2,240 $ 2.03 Options granted (962 ) 962 3.58 Options exercised - (100 ) 2.19 Options forfeited, cancelled or expired 85 (85 ) 2.00 Total at December 31, 2016 880 3,017 $ 2.52 Exercisable at December 31, 2016 1,591 $ 1.83 At December 31, 2016 and 2015, OncoCyte had approximately $2.7 million and $1.5 million, respectively, of total unrecognized compensation expense, net of estimated forfeitures, related to the Plan that will be recognized over a weighted-average period of approximately 2.4 and 3.0 years, respectively. OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2016, 2015 and 2014 (in thousands): 2016 2015 2014 Research and development $ 312 $ 456 $ 177 General and administrative 610 1,359 141 Total stock-based compensation expense $ 922 $ 1,815 $ 318 The assumptions that were used to calculate the grant date fair value of OncoCyte’s employee and non-employee stock option grants for the years ended December 31, 2016, 2015 and 2014 were as follows. 2016 2015 2014 (1) Expected life (in years) 6.21 6.83 - Risk-free interest rates 1.46 % 1.87 % - % Volatility 64.64 % 74.15 % - % Dividend yield - % - % - % (1) No stock options were granted in 2014. Stock-based compensation expense is recognized based on awards that are ultimately expected to vest, and as a result, the amount has been reduced by estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on OncoCyte’s historical experience and future expectations. The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If OncoCyte had made different assumptions, its stock-based compensation expense, and net loss for years ended December 31, 2016, 2015 and 2014, may have been significantly different. There was no net income tax benefit recognized in the statements of operations for stock-based compensation expense for non-qualified stock options, as OncoCyte fully offsets net deferred tax assets with a valuation allowance (see Note 8). In addition, OncoCyte does not recognize deferred income taxes for incentive stock option compensation expense, and records a tax deduction only when a disqualified disposition has occurred.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Income Taxes	8. Income Taxes OncoCyte has filed standalone U.S. federal income tax returns since its inception. For California purposes, OncoCyte’s activity for 2015 and 2016 has been or will be included in BioTime’s California Combined tax return. The provision for income taxes has been determined as if OncoCyte had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The deferred tax assets, including the operating loss and credit carryforwards, generated by OncoCyte, will remain with OncoCyte. The primary components of the deferred tax assets and liabilities at December 31, 2016 and 2015 were as follows (in thousands): 2016 2015 Deferred liabilities: Available-for-sale securities $ (761 ) $ (864 ) Total deferred tax liabilities (761 ) (864 ) Deferred tax assets: Net operating loss carryforwards 11,730 8,139 Research and development credit carryforwards 1,765 1,362 Patents and fixed assets 179 136 Stock-based compensation and accrued payroll 1,041 98 Valuation Allowance (13,954 ) (8,871 ) Total deferred tax assets 761 864 Net deferred tax asset (liability) $ - $ - Due to losses incurred for all periods presented, OncoCyte did not record any provision or benefit for income taxes. Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following: 2016 2015 2014 Computed tax benefit at federal statutory rate 34 % 34 % 34 % Permanent differences (1 %) (9 %) (2 %) State tax benefit 2 % 15 % - Research and development credits 2 % 2 % 2 % Other 7 % 3 % - Change in valuation allowance (44 %) (45 %) (34 %) - % - % - % As of December 31, 2016, OncoCyte has net operating loss carryforwards of approximately $30.6 million for U.S. federal income tax purposes and $15.1 million for state income tax purposes. Federal net operating loss carryforwards expire from 2030 and 2036, and state carryforwards expire from 2029 and 2036. In addition, as of December 31, 2016, OncoCyte has research and development credit carryforwards for federal and state purposes of $860,000 and $905,000, respectively. The federal credits will expire between 2030 and 2036, while the state credits have no expiration. During 2015, OncoCyte sold 259,712 BioTime common shares, in at-the-market transactions which resulted in taxable gains of approximately $815,000. These taxable gains were fully offset by current operating losses, thus resulting in no income taxes due from the sales. At December 31, 2016 and 2015, OncoCyte recorded deferred tax liabilities of $761,000 and $864,000 resulting from the difference in the tax basis of BioTime shares held as compared to the basis of those shares reported for financial reporting purposes (see Note 2). A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. OncoCyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The change in the valuation allowance was $5.1 million and $3.9 million for the years ended December 31, 2016 and 2015, respectively. Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by net operating loss (“NOL”) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. There has not been a change in ownership for any of the periods presented. OncoCyte may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. In general, OncoCyte is no longer subject to tax examination by major taxing authorities for years before 2011. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies OncoCyte had no commitments other than those under the Shared Facilities and Services Agreement described in Note 4. The minimum fixed payments due under the Shared Facilities Agreement are approximately $15,000 per month. Tax Filings OncoCyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes OncoCyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the financial statements. Master Lease Line Agreement On April 7, 2016, OncoCyte entered into a Master Lease Line Agreement (the “Lease Agreement”) with an unrelated financing company for the purchase and financing of certain equipment. OncoCyte may use up to $875,000 for purchases of equipment financed by the Lease Agreement between March 29, 2016 through March 28, 2017, the expiration date of the availability of funds under the Lease Agreement. Each lease schedule OncoCyte enters into under the Lease Agreement must be in minimum increments of $50,000 each with a 36-month lease term, collateralized by the equipment financed under the lease schedule. Each lease schedule requires a deposit for the first and last payment under that schedule. Monthly payments will be determined using a lease factor approximating an interest rate of 10% per annum. At the end of each lease schedule under the Lease Agreement, assuming no default has occurred, OncoCyte may either return the equipment financed under the schedule for a restocking fee of 7.5% of the original cost of the equipment or purchase the equipment from the financing company at a fair value not less than 12.5% of the original cost of the equipment. On April 7, 2016, OncoCyte entered into a lease schedule under the Lease Agreement for certain equipment costing approximately $458,000, requiring payments of $14,442 per month over 36 months. In December 2016, OncoCyte entered into a lease schedule under the Lease Agreement for certain equipment costing approximately $168,000, requiring payments of $5,342 per month over 36 months. OncoCyte has accounted for these leases as a capital lease in accordance with ASC 840, Leases Litigation – General OncoCyte will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When OncoCyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, OncoCyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, OncoCyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. OncoCyte is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. Employment Contracts OncoCyte has entered into employment contracts with certain executive officers. Under the provisions of the contracts, OncoCyte may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations. At December 31, 2016, total potential severance obligations in connection with the termination of employment contracts approximated $420,000 for termination without cause and $624,000 for termination due to a change in control. Indemnification In the normal course of business, OncoCyte may provide indemnification of varying scope under OncoCyte’s agreements with other companies or consultants, typically OncoCyte’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, OncoCyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of OncoCyte’s diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to OncoCyte’s diagnostic tests. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments OncoCyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, OncoCyte has not been subject to any claims or demands for indemnification. OncoCyte also maintains various liability insurance policies that limit OncoCyte’s financial exposure. As a result, OncoCyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, OncoCyte has not recorded any liabilities for these agreements as of December 31, 2016 and 2015.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events On February 17, 2017, certain of OncoCyte investors exercised 625,000 offering Warrants at an exercise price of $3.25 per warrant for total exercise cash proceeds of $2.0 million (the “Warrant exercise”). The offering Warrants had been issued as part of OncoCyte’s financing that was completed on August 29, 2016. See Note 6. In order to induce the investors to complete the Warrant exercise and, in conjunction with the Warrant exercise, OncoCyte issued new warrants to those investors (the “New Warrants”). Certain investors received 200,000 New Warrants with an exercise price of $5.50 per warrant share and the other investor received 212,500 New Warrants with an exercise of $3.25 per warrant share. The New Warrants are exercisable at any time for five years from February 16 and 17, 2017, respectively. After the Warrant exercise and issuance of the New Warrants to those investors, OncoCyte has an aggregate of 3,033,653 warrants, including the offering Warrants and New Warrants, outstanding at exercise prices ranging from $3.25 and $5.50 per warrant. As a result of the issuance of 625,000 shares of OncoCyte common stock from the Warrant exercise, as of February 17, 2017, BioTime owned less than 50% of the OncoCyte outstanding common stock. Under GAAP, loss of control of a subsidiary is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock of the subsidiary, lacks a controlling financial interest in the subsidiary, and is unable to unilaterally control the subsidiary through other means such as having the ability or being able to obtain the ability to elect a majority of the subsidiary’s Board of Directors. BioTime determined that all of these loss of control factors were present for BioTime as of February 17, 2017. Accordingly, BioTime has deconsolidated OncoCyte’s financial statements and results of operations from BioTime, effective February 17, 2017, in accordance with ASC, 810-10-40-4(c), Consolidation . On February 21, 2017, OncoCyte entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (the “Bank”) pursuant to which OncoCyte obtained a $2 million secured credit facility, (the “First Tranche”). If OncoCyte wishes to borrow the First Tranche, it must do so by April 30, 2017. The credit line may be increased by $3 million (the “Contingent Tranche”) on or after May 1, 2017 if OncoCyte obtains at least $20 million of additional equity capital and launches its initial lung cancer diagnostic test, and is not in default under the Loan Agreement. Payments of interest only on the principal balance will be due monthly from the draw date through October 31, 2017, and, beginning on November 1, 2017, monthly payments of principal and interest will become payable. The outstanding principal balance of the loan will bear interest at a stated floating annual interest rate equal to the greater of (i) three-quarters of one percent (0.75%) above the prime rate or (ii) four and one-quarter percent (4.25%). As of February 21, 2017, the prime rate plus 0.75% was 4.50% per annum. The principal amount of the First Tranche plus accrued interest will be due and payable to the Bank at maturity on April 1, 2020. The principal amount of all draws under the Contingent Tranche, if any, plus accrued interest will be due and payable to the Bank at maturity on October 1, 2020. At maturity, OncoCyte will also pay the Bank an additional final payment fee of 5.8% of the original principal borrowed. Any amounts borrowed and repaid, may not be reborrowed. OncoCyte may prepay in full the outstanding principal balance at any time, subject to a prepayment fee equal to 3.0% of the outstanding principal balance if prepaid within one year after the February 21, 2017, 2.0% of the outstanding principal balance if prepaid more than one year but less than two years after the February 21, 2017, or 1.0% of the outstanding principal balance if prepaid two years or more after the February 21, 2017. The outstanding principal amount of the loan, with interest accrued, the final payment fee, and the prepayment fee may become due and payable prior to the applicable maturity date if an “Event of Default” as defined in the Loan Agreement occurs and is not cured within any applicable cure period. An Event of Default includes, among other events, failure to pay interest and principal when due, material adverse changes, which include a material adverse change in OncoCyte’s business, operations, or condition (financial or otherwise), failure to provide the bank with timely financial statements and filings with the Securities and Exchange Commission, as required, legal judgments or pending or threatened legal actions of $50,000 or more, insolvency, and delisting from the NYSE MKT. OncoCyte’s obligations under the Loan Agreement are collateralized by substantially all of its assets other than intellectual property such as patents and trade secrets that OncoCyte owns. On February 21, 2017 and in conjunction with the $2 million First Tranche becoming available under the Loan Agreement, OncoCyte issued a common stock purchase warrant to the Bank (the “Bank Warrant”) entitling the Bank to purchase 8,247 shares of OncoCyte common stock at the initial Warrant Price of $4.85 per share through February 21, 2027. The number of shares of common stock issuable upon the exercise of the Bank Warrant will increase on the date of the draw of the First Tranche, and on the date on which OncoCyte meets the conditions of the Contingent Tranche availability, and on the date of the first draw, if any, on the Contingent Tranche. The number of additional shares of common stock issuable upon the exercise of the Bank Warrant will be equal to 2.0% of the First Tranche or Contingent Tranche, as applicable, divided by the Warrant Price determined as provided in the Bank Warrant. The Warrant Price will be determined with reference to the market price of OncoCyte common stock on the date the Contingent Tranche becomes available, or the date on which OncoCyte borrows funds under the First Tranche or Contingent Tranche, as applicable. The Bank may elect to exercise the Bank Warrant on a “cashless exercise” basis and receive a number of shares determined by multiplying the number of shares for which the Bank Warrant is being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market. On February 17, 2017, OncoCyte granted 357,130 stock options to employees with an exercise price of $4.70 per share, determined based on the closing price of the OncoCyte common stock immediately prior to the grant date in accordance with the Plan, subject to standard vesting conditions.

Organization, Basis of Presenta

Organization, Basis of Presentation and Liquidity (Policies)	12 Months Ended
	Dec. 31, 2016
Organization, Description of the Business and Liquidity [Abstract]
Liquidity	Liquidity For all periods presented, OncoCyte had generated no revenues. Since inception, OncoCyte has financed its operations through the sale of its common stock and warrants to its shareholders, including BioTime, loans from BioTime and other BioTime affiliates, warrant exercises, and a bank loan (see Note 10), and sales of BioTime common shares that OncoCyte held as available-for-sale securities (see Note 2). OncoCyte has incurred operating losses and negative cash flows since inception, and had an accumulated deficit of $35.3 million and $24.1 million as December 31, 2016 and 2015, respectively. OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte’s research and development efforts are successful to the point where it believes that a commercial product can be launched successfully, then additional capital will be required for developing a sales and marketing team and launching OncoCyte’s first diagnostic test. Dependent on results of any product commercialization and ongoing sales, if any, additional capital might be required in 2017 or beyond to develop and launch products, for working capital, and for other expenses. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all. At December 31, 2016, we had $10.2 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $2.2 million. On February 17, 2017, OncoCyte received cash proceeds of $2.0 million when certain investors exercised 625,000 warrants to purchase OncoCyte common stock at an exercise price of $3.25 per share. The warrants had been issued as part of a financing that was completed on August 29, 2016, through which OncoCyte sold an aggregate of 3,246,153 immediately separable “units”, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (see Note 10). On February 21, 2017, OncoCyte entered into a Loan and Security Agreement with Silicon Valley Bank for a working capital loan of $2 million, collateralized by substantially all of OncoCyte’s assets other than intellectual property such as patents and trade secrets that OncoCyte owns (see Note 10). Based on cash and cash equivalents currently on hand, including the warrant exercises and working capital loan under the Loan Agreement discussed above and in Note 10, OncoCyte believes it has sufficient cash, cash equivalents, available for sale securities and working capital to carry out its current operations through at least twelve months from the issuance date of the financial statements included herein (see Note 2).

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The financial statements presented herein have been prepared on a separate, stand-alone basis. The financial statements are presented in accordance with U.S. generally accepted accounting principles (“GAAP”). BioTime has consolidated the results of OncoCyte into BioTime’s consolidated results based on BioTime’s ability to control OncoCyte’s operating and financial decisions and policies through its majority ownership of OncoCyte common stock throughout the periods presented. BioTime owned 51.1% and 57.7% of the outstanding common stock of OncoCyte at December 31, 2016 and 2015, respectively. As more fully discussed in Note 10, on February 17, 2017, BioTime’s percentage ownership of the outstanding OncoCyte common stock declined below 50%, resulting in a loss of “control,” of OncoCyte as under GAAP and a result, BioTime deconsolidated OncoCyte’s financial statements from BioTime’s consolidated financial statements. As a result of this deconsolidation, OncoCyte is no longer considered a subsidiary of BioTime under GAAP as of February 17, 2017. OncoCyte remains an affiliate of BioTime based on BioTime’s retained share ownership in OncoCyte which is sufficient to allow BioTime to exert significant influence over the operations and management of OncoCyte. To the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to OncoCyte’s operations or management. Management evaluates the appropriateness of the percentage allocations on a quarterly basis and believes that this basis for allocation is reasonable. As further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of operations for the services performed in the periods presented.
Reverse stock split	Reverse stock split On November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes, where applicable, to reflect the impact of the reverse stock split.
Use of estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including those related to going concern assessment of OncoCyte financial statements, the allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates.
Going concern assessment	Going concern assessment With the implementation of FASB’s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte will assess going concern uncertainty in its financial statements to determine if it has sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the “look-forward period” as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.
Fair value measurements	Fair value measurements OncoCyte accounts for fair value measurements in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements · Level 1 · Level 2 · Level 3 In determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.
Cash and cash equivalents	Cash and cash equivalents Cash equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December 31, 2016 and 2015, OncoCyte's cash balances totaled $10.2 million and $8.0 million, respectively, and consist of bank account deposits and $9.4 million held in money market funds at December 31, 2016. Financial instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies. OncoCyte places its cash and cash equivalents with high credit quality financial institutions.
Accounting for BioTime shares	Accounting for BioTime shares OncoCyte accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25, Investments – Debt and Equity Securities As discussed in Note 10, on February 17, 2017, as a result of a loss of control experienced by BioTime on OncoCyte due to BioTime’s reduced ownership to below 50% of OncoCyte outstanding common stock, BioTime deconsolidated OncoCyte’s financial statements from BioTime’s consolidated financial statements. Due to this deconsolidation and BioTime no longer having a controlling financial interest in OncoCyte’s operations and financial statements, any realized gains and losses OncoCyte generates from the sale of BioTime shares, beginning on February 17, 2017, will be included in OncoCyte’s statements of operations. As of December 31, 2016, OncoCyte held 619,706 BioTime common shares as available-for-sale securities with a fair market value of $2.2 million.
Long-lived intangible assets	Long-lived intangible assets Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years.
Equipment and furniture	Equipment and furniture Equipment and furniture are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under capital leases, OncoCyte depreciates the equipment based on the lower of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the capital lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in OncoCyte’s results of operations.
Impairment of long-lived assets	Impairment of long-lived assets OncoCyte assesses the impairment of long-lived assets, which consist primarily of long-lived intangible assets, furniture and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset’s carrying value over its fair value is recorded. Through 2016, there have been no such impairment losses.
Accounting for warrants	Accounting for warrants OncoCyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity , then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock . Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate OncoCyte to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, OncoCyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, OncoCyte also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, OncoCyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require to be accounted for at fair value at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. OncoCyte does not have any liability classified warrants as of any period presented. See Note 6.
Income taxes	Income taxes OncoCyte has filed a standalone U.S. federal income tax return since its inception. For California purposes, OncoCyte’s activity for 2015 and 2016 has been or will be included in BioTime’s California combined tax return. The provision for income taxes has been determined as if OncoCyte had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by OncoCyte, will remain with OncoCyte. OncoCyte accounts for income taxes in accordance with ASC 740, Income Taxes The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. OncoCyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2016 and 2015. OncoCyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2016 and 2015. OncoCyte is currently unaware of any tax issues under review.
Research and development expenses	Research and development expenses Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, and expenses for outside consultants. These expenses include both direct and allocated or indirect overhead costs allocated by BioTime (see Note 4). Research and development costs are expensed as incurred.
General and administrative expenses	General and administrative expenses OncoCyte’s general and administrative expenses relate primarily to compensation and related benefits, including stock-based compensation, for executive and corporate personnel, including direct costs and costs allocated by BioTime; professional and consulting fees; direct overhead and indirect overhead allocated by BioTime (see Note 4).
Stock-based compensation	Stock-based compensation OncoCyte recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718, Compensation – Stock Compensation OncoCyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures, over the requisite service period. OncoCyte uses the Black-Scholes option pricing model for estimating the fair value of options granted under OncoCyte’s Stock Option Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. OncoCyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis, net of estimated forfeitures, over the requisite service period. Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718 and FASB ASC 505-50, Equity-Based Payments to Non-Employees The Black-Scholes option pricing model requires OncoCyte to make certain assumptions including the fair value of the underlying common stock, the expected option term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 7). The fair value of the shares of common stock underlying the stock options has historically been determined by the Board of Directors. Because there was no public market for OncoCyte’s common stock prior to December 31, 2015, the Board of Directors determined the fair value of the common stock at the time of the grant of options by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, among other factors in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled Valuation of Privately Held Company Equity Securities Issued As Compensation The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. OncoCyte estimates the expected term of options granted based upon the “simplified method” provided under Staff Accounting Bulletin, Topic 14 Because OncoCyte’s common stock had no public trading history prior to December 31, 2015, for the years ended December 31, 2015 and 2014, OncoCyte estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to OncoCyte, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the year ended December 31, 2016, OncoCyte estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of stock of peer companies. OncoCyte determined the expected volatility assumption using the frequency of daily historical prices of comparable public company’s common stock for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of OncoCyte’s stock options. The dividend yield assumption is based on OncoCyte’s history and expectation of dividend payouts. OncoCyte has never declared or paid any cash dividends on its common stock, and OncoCyte does not anticipate paying any cash dividends in the foreseeable future.
Net loss per common share	Net loss per common share Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the weighted-average number of shares of common stock outstanding plus the potential effect of dilutive securities or contracts which are convertible to common stock, such as stock options (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Because OncoCyte reported net losses for all periods presented, all potentially dilutive common stock are antidilutive for those periods. The computations of basic and diluted net loss per common share for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands, except per share amounts): 2016 2015 2014 Net loss $ (11,168 ) $ (8,735 ) $ (4,986 ) Weighted average common shares outstanding – basic and diluted 26,529 21,009 18,200 Net loss per common share – basic and diluted $ (0.42 ) $ (0.42 ) $ (0.27 ) The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2016, 2015 and 2014 because including them would have been antidilutive (in thousands): 2016 2015 2014 Stock options under Stock Option Plan 3,017 2,240 1,361 Warrants 3,246 - -
Segments	Segments OncoCyte’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, OncoCyte’s executive management team has viewed OncoCyte’s operations as one segment that includes, the research and development of diagnostic tests for the detection of cancer. As a result, the financial information disclosed materially represents all of the financial information related to OncoCyte’s sole operating segment.
Recent accounting pronouncements	Recent accounting pronouncements The following accounting standards, which are not yet effective, are presently being evaluated by OncoCyte to determine the impact that they might have on its financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). In April 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing”. The amendments clarify two aspects of Topic 606: (a) identifying performance obligations; and (b) the licensing implementation guidance. The update is effective for annual periods beginning after December 15, 2017 including interim reporting periods therein. OncoCyte does not expect the adoption of ASC 606 will have a material impact on its financial statements. On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” (ASU No. 2016-01). Changes to the current GAAP model primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU No. 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU No. 2016-01, when adopted, could have a material impact to OncoCyte’s financial statements based on the current accounting for shares of BioTime common stock OncoCyte holds as available-for-sale securities. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those annual periods. Early adoption is permitted. OncoCyte is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements. In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The update is effective for fiscal years beginning after December 15, 2016. OncoCyte is currently evaluating the impact the adoption of ASU 2016-09 will have on its financial statements.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Computations of Basic and Diluted Net Loss Per Share	The computations of basic and diluted net loss per common share for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands, except per share amounts): 2016 2015 2014 Net loss $ (11,168 ) $ (8,735 ) $ (4,986 ) Weighted average common shares outstanding – basic and diluted 26,529 21,009 18,200 Net loss per common share – basic and diluted $ (0.42 ) $ (0.42 ) $ (0.27 )
Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share of Common Stock	The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2016, 2015 and 2014 because including them would have been antidilutive (in thousands): 2016 2015 2014 Stock options under Stock Option Plan 3,017 2,240 1,361 Warrants 3,246 - -

Selected Balance Sheet Compon21

Selected Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2016
Selected Balance Sheet Components [Abstract]
Prepaid Expenses and Other Current Assets	At December 31, 2016 and 2015, prepaid expenses and other current assets were comprised of the following (in thousands): 2016 2015 Outside research $ - $ 366 Insurance 182 - Other prepaid expenses and current asset 103 22 Prepaid expenses and other current assets $ 285 $ 388
Accrued Expenses and Other Current Liabilities	At December 31, 2016 and 2015, accrued expenses and other current liabilities were comprised of the following (in thousands): 2016 2015 Accrued bonuses and payroll related expenses $ 549 $ 325 Other accrued expenses 248 857 Accrued expenses and other current liabilities $ 797 $ 1,182
Intangible Assets, Net	At December 31, 2016 and 2015, intangible assets were comprised of the following (in thousands): 2016 2015 Intangible assets $ 2,419 $ 2,419 Accumulated amortization (1,431 ) (1,189 ) Intangible assets, net $ 988 $ 1,230
Equipment and Furniture, Net	At December 31, 2016 and 2015, equipment and furniture were comprised of the following (in thousands): 2016 2015 Equipment and furniture $ 1,007 $ 750 Accumulated depreciation (319 ) (174 ) Equipment and furniture, net $ 688 $ 576

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Stock-based Compensation [Abstract]
Summary of Stock Option Activity	A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price): Options Available for Grant Number of Options Outstanding Weighted Average Exercise Price Total at January 1, 2015 639 1,361 $ 1.52 Increase in option pool 2,000 - Options granted (1,448 ) 1,448 2.21 Options exercised - (3 ) 1.34 Options forfeited or cancelled 566 (566 ) 1.59 Total at December 31, 2015 1,757 2,240 $ 2.03 Options granted (962 ) 962 3.58 Options exercised - (100 ) 2.19 Options forfeited, cancelled or expired 85 (85 ) 2.00 Total at December 31, 2016 880 3,017 $ 2.52 Exercisable at December 31, 2016 1,591 $ 1.83
Categories of Stock-based Compensation Expense	OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2016, 2015 and 2014 (in thousands): 2016 2015 2014 Research and development $ 312 $ 456 $ 177 General and administrative 610 1,359 141 Total stock-based compensation expense $ 922 $ 1,815 $ 318
Assumptions used to Calculate Fair Value of Stock Options	The assumptions that were used to calculate the grant date fair value of OncoCyte’s employee and non-employee stock option grants for the years ended December 31, 2016, 2015 and 2014 were as follows. 2016 2015 2014 (1) Expected life (in years) 6.21 6.83 - Risk-free interest rates 1.46 % 1.87 % - % Volatility 64.64 % 74.15 % - % Dividend yield - % - % - % (1) No stock options were granted in 2014.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Components of Deferred Tax Assets and Liabilities	The primary components of the deferred tax assets and liabilities at December 31, 2016 and 2015 were as follows (in thousands): 2016 2015 Deferred liabilities: Available-for-sale securities $ (761 ) $ (864 ) Total deferred tax liabilities (761 ) (864 ) Deferred tax assets: Net operating loss carryforwards 11,730 8,139 Research and development credit carryforwards 1,765 1,362 Patents and fixed assets 179 136 Stock-based compensation and accrued payroll 1,041 98 Valuation Allowance (13,954 ) (8,871 ) Total deferred tax assets 761 864 Net deferred tax asset (liability) $ - $ -
Income Tax Reconciliation	Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following: 2016 2015 2014 Computed tax benefit at federal statutory rate 34 % 34 % 34 % Permanent differences (1 %) (9 %) (2 %) State tax benefit 2 % 15 % - Research and development credits 2 % 2 % 2 % Other 7 % 3 % - Change in valuation allowance (44 %) (45 %) (34 %) - % - % - %

Organization, Description of 24

Organization, Description of the Business and Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 17, 2017	Aug. 29, 2016	Feb. 21, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Equity Method Investments [Line Items]
Equity ownership percentage		51.20%
Accumulated deficit				$ (35,302)	$ (24,134)
Cash and cash equivalents				10,174	7,996	$ 257	$ 101
BioTime shares held as available-for-sale securities, at fair value				$ 2,237	$ 2,541
Proceeds from sale of stock		$ 9,800
Issuance of common stock and warrants (in shares)		3,246,153
Warrant exercise price (in dollars per share)				$ 3.25
Warrants to purchase stock in each separable unit (in shares)		1
Number of common shares available in each separable unit (in shares)		1
Subsequent Event [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from sale of stock	$ 2,000
Issuance of common stock and warrants (in shares)	625,000
Warrant exercise price (in dollars per share)	$ 3.25
BioTime, Inc. [Member]
Schedule of Equity Method Investments [Line Items]
Equity ownership percentage				51.10%	57.70%
BioTime shares held as available-for-sale securities, at fair value				$ 2,200
Warrants to purchase stock in each separable unit (in shares)		1
Number of common shares available in each separable unit (in shares)		1
BioTime, Inc. [Member] | Subsequent Event [Member]
Schedule of Equity Method Investments [Line Items]
Equity ownership percentage	50.00%
Proceeds from sale of stock	$ 2,000
Issuance of common stock and warrants (in shares)	625,000
Warrant exercise price (in dollars per share)	$ 3.25
BioTime, Inc. [Member] | Maximum [Member] | Subsequent Event [Member]
Schedule of Equity Method Investments [Line Items]
Equity ownership percentage	50.00%
Additional capital			$ 2,000

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Details) $ / shares in Units, $ in Thousands	Nov. 18, 2015	Dec. 31, 2016USD ($)Segment$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Feb. 17, 2017	Aug. 29, 2016
Schedule of Equity Method Investments [Line Items]
Equity ownership percentage						51.20%
Reverse Stock Split [Abstract]
Reverse stock split ratio	0.5
Cash and Cash Equivalents [Abstract]
Cash		$ 10,200	$ 8,000
Money market funds		9,400
Subsidiary, Sale of Stock [Line Items]
Shares held as available-for-sale securities, at fair value		$ 2,237	2,541
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life		10 years
Impairment of long-lived assets [Abstract]
Impairment losses		$ 0
Income Taxes [Abstract]
Accrued interest and penalties		0	0
Computations of Basic and Diluted Net Loss Per Common Share [Abstract]
Net loss		$ (11,168)	$ (8,735)	$ (4,986)
Weighted average shares outstanding - basic and diluted (in shares) | shares		26,529,000	21,009,000	18,200,000
Net loss per common share - basic and diluted (in dollars per share) | $ / shares		$ (0.42)	$ (0.42)	$ (0.27)
Segments [Abstract]
Number of operating segments | Segment		1
Equipment and Furniture [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Equipment and furniture, useful life		3 years
Equipment and Furniture [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Equipment and furniture, useful life		10 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Equipment and furniture, useful life		3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Equipment and furniture, useful life		5 years
BioTime, Inc. [Member]
Schedule of Equity Method Investments [Line Items]
Equity ownership percentage		51.10%	57.70%
Subsidiary, Sale of Stock [Line Items]
Shares held as available-for-sale securities (in shares) | shares		619,706
Shares held as available-for-sale securities, at fair value		$ 2,200
BioTime, Inc. [Member] | Subsequent Event [Member]
Schedule of Equity Method Investments [Line Items]
Equity ownership percentage					50.00%
BioTime, Inc. [Member] | Maximum [Member] | Subsequent Event [Member]
Schedule of Equity Method Investments [Line Items]
Equity ownership percentage					50.00%
Long-lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life		10 years
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares) | shares		3,017,000	2,240,000	1,361,000
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares) | shares		3,246,000	0	0

Selected Balance Sheet Compon26

Selected Balance Sheet Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Prepaid expenses and other current assets [Abstract]
Outside research	$ 0	$ 366
Insurance	182	0
Other prepaid expenses and current asset	103	22
Prepaid expenses and other current assets	285	388
Accrued expenses and other current liabilities [Abstract]
Accrued bonuses and payroll related expenses	549	325
Other accrued expenses	248	857
Accrued expenses and other current liabilities	$ 797	1,182
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	10 years
Amortization expense	$ 242	242	$ 242
Intangible assets, net [Abstract]
Intangible assets	2,419	2,419
Accumulated amortization	(1,431)	(1,189)
Intangible assets, net	988	1,230
Equipment and furniture, net [Abstract]
Equipment and furniture	1,007	750
Accumulated depreciation	(319)	(174)
Equipment and furniture, net	688	576
Depreciation expense	145	$ 41	$ 39
Laboratory equipment value	$ 626

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current Liabilities [Member]
Shared Facilities and Service Agreement [Abstract]
Allocated use fees payable	$ 2,900,000	$ 847,000
General and Administrative Expenses [Member]
Shared Facilities and Service Agreement [Abstract]
Allocated use fees	790,000	595,000	$ 344,000
Research and Development [Member]
Shared Facilities and Service Agreement [Abstract]
Allocated use fees	$ 691,000	$ 565,000	$ 552,000
BioTime, Inc. [Member]
Shared Facilities and Service Agreement [Abstract]
Markup rate on allocated costs	5.00%
Term of payment	30 days
Interest rate charged on unpaid and overdue invoices	15.00%

Related Party Convertible Pro28

Related Party Convertible Promissory Note Payable (Details)	1 Months Ended		12 Months Ended
	Nov. 30, 2015shares	May 31, 2015USD ($)Shareholdershares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Related Party Transaction [Line Items]
Fair value of the common stock on the date of the exchange			$ 0	$ 3,300,000	$ 0
First Subscription Agreement [Member] | Investors [Member]
Related Party Transaction [Line Items]
Number of shareholders | Shareholder		2
First Subscription Agreement [Member] | Investors [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Number of shareholders | Shareholder		2
First Subscription Agreement [Member] | BioTime, Inc. [Member] | Convertible Promissory Note [Member]
Related Party Transaction [Line Items]
Convertible note delivered to BioTime		$ 3,300,000
Issuance date fair value of the Note		3,300,000
First Subscription Agreement [Member] | BioTime, Inc. [Member] | Long-term Debt [Member]
Related Party Transaction [Line Items]
Extinguishment of debt amount		6,600,000
Gain (loss) on extinguishment of debt		$ 0
First Subscription Agreement [Member] | BioTime, Inc. [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Common stock issued in exchange of indebtedness (in shares) | shares		1,500,000
Indebtedness cancelled		$ 3,300,000
Fair value of the common stock on the date of the exchange		$ 3,300,000
First Subscription Agreement [Member] | BioTime, Inc. [Member] | Common Stock [Member] | Convertible Promissory Note [Member]
Related Party Transaction [Line Items]
Common stock issued in exchange of indebtedness (in shares) | shares	1,508,095

Shareholders' Equity (Details)

Shareholders' Equity (Details) $ / shares in Units, $ in Thousands	Aug. 29, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)shares	May 31, 2015USD ($)Shareholder$ / sharesshares	Dec. 31, 2016USD ($)Vote$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)				5,000,000	5,000,000
Preferred stock, par value (in dollars per share) | $ / shares				$ 0	$ 0
Preferred stock, shares issued (in shares)				0	0
Preferred stock, shares outstanding (in shares)				0	0
Common Stock [Abstract]
Common stock, shares authorized (in shares)				50,000,000	50,000,000
Common shares, par value (in dollars per share) | $ / shares				$ 0	$ 0
Number of votes for each share | Vote				1
Proceeds from issuance of stock | $				$ 0	$ 11,649	$ 0
Issuance of common stock and warrants (in shares)	3,246,153
Warrants to purchase stock in each separable unit (in shares)	1
Number of common shares available in each separable unit (in shares)	1
Separable units, exercise price (in dollars per share) | $ / shares	$ 3.25
Percentage of ownership interest	51.20%
Proceeds from equity financing after discounts, commission and expenses | $	$ 9,800
Contingently Issuable Common Stock Warrants [Abstract]
Warrant exercise price (in dollars per share) | $ / shares				$ 3.25
Warrant exercised period				5 years
BioTime, Inc. [Member]
Common Stock [Abstract]
Warrants to purchase stock in each separable unit (in shares)	1
Number of common shares available in each separable unit (in shares)	1
Percentage of ownership interest				51.10%	57.70%
First Subscription Agreement [Member] | Investors [Member]
Common Stock [Abstract]
Number of shareholders | Shareholder			2
First Subscription Agreement [Member] | Investors [Member] | Common Stock [Member]
Common Stock [Abstract]
Number of shareholders | Shareholder			2
Common stock, shares issued (in shares)			1,500,000
Proceeds from issuance of stock | $			$ 3,300
Issue price per share (in dollars per share) | $ / shares			$ 2.20
First Subscription Agreement [Member] | BioTime, Inc. [Member] | Common Stock [Member]
Common Stock [Abstract]
Common stock, shares issued (in shares)		2,710,857
Proceeds from issuance of stock | $		$ 8,300
Common stock issued in exchange of indebtedness (in shares)			1,500,000
Indebtedness cancelled | $			$ 3,300
Common stock received as dividend in kind (in shares)					30,985
Common stock shares converted (in shares)					20

Stock-based Compensation (Detai

Stock-based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014		Aug. 29, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of ownership interest					51.20%
Share-based Compensation [Abstract]
Share-based compensation expense	$ 922,000	$ 1,815,000	$ 318,000
Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for exercising vested option	12 months
Shares Available for Grant [Roll Forward]
Outstanding, beginning of the period (in shares)	1,757,000	639,000
Increase in option pool (in shares)		2,000,000
Options granted (in shares)	(962,000)	(1,448,000)
Options exercised (in shares)	0	0
Options forfeited or cancelled (in shares)	85,000	566,000
Outstanding, end of the period (in shares)	880,000	1,757,000	639,000
Number of Options Outstanding [Roll Forward]
Outstanding, beginning of the period (in shares)	2,240,000	1,361,000
Option granted (in shares)	962,000	1,448,000	0
Options exercised (in shares)	(100,000)	(3,000)
Options forfeited, cancelled or expired (in shares)	(85,000)	(566,000)
Outstanding, end of the period (in shares)	3,017,000	2,240,000	1,361,000
Exercisable (in shares)	1,591,000
Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of the period (in dollars per share)	$ 2.03	$ 1.52
Option granted (in dollars per share)	3.58	2.21
Options exercised (in dollars per share)	2.19	1.34
Options forfeited or cancelled (in dollars per share)	2	1.59
Outstanding end of the period (in dollars per share)	2.52	$ 2.03	$ 1.52
Exercisable (in dollars per share)	$ 1.83
Total unrecognized compensation costs	$ 2,700,000	$ 1,500,000
Weighted average recognition period	2 years 4 months 24 days	3 years
Share-based Compensation [Abstract]
Share-based compensation expense	$ 922,000	$ 1,815,000	$ 318,000
Weighted-average assumptions [Abstract]
Expected life	6 years 2 months 16 days	6 years 9 months 29 days	0 years	[1]
Risk-free interest rates	1.46%	1.87%	0.00%	[1]
Volatility	64.64%	74.15%	0.00%	[1]
Dividend yield	0.00%	0.00%	0.00%	[1]
Stock Option Plan [Member] | Research and Development [Member]
Share-based Compensation [Abstract]
Share-based compensation expense	$ 312,000	$ 456,000	$ 177,000
Stock Option Plan [Member] | General and Administrative [Member]
Share-based Compensation [Abstract]
Share-based compensation expense	$ 610,000	$ 1,359,000	$ 141,000
Stock Option Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of ownership interest	10.00%
Percentage of fair market value of common stock	110.00%
Stock Option Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of options	5 years
Aggregate fair value of common stock	$ 100,000
Period of nontransferable for stock option grants	3 months
2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (in shares)		2,000,000
Maximum period for options grants in period	10 years
Maximum period for options exercises in period	10 years
[1]	No stock options were granted in 2014.

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred liabilities [Abstract]
Available-for-sale securities	$ (761)	$ (864)
Total deferred tax liabilities	(761)	(864)
Deferred tax assets [Abstract]
Net operating loss carryforwards	11,730	8,139
Research and development credit carryforwards	1,765	1,362
Patents and fixed assets	179	136
Stock-based compensation	1,041	98
Valuation Allowance	(13,954)	(8,871)
Total deferred tax assets	761	864
Net deferred tax asset (liability)	$ 0	$ 0
Income Tax Reconciliation [Abstract]
Computed tax benefit at federal statutory rate	34.00%	34.00%	34.00%
Permanent differences	(1.00%)	(9.00%)	(2.00%)
State tax benefit	2.00%	15.00%	0.00%
Research and development credits	2.00%	2.00%	2.00%
Other	7.00%	3.00%	0.00%
Change in valuation allowance	(44.00%)	(45.00%)	(34.00%)
Total	0.00%	0.00%	0.00%
Class of Stock [Line Items]
Company share in market transactions (in shares)	28,737,000	25,391,000
Change in valuation allowance	$ 5,100	$ 3,900
Percentage of change in ownership	50.00%
Period in which change of ownership for a specified percentage should occur	3 years
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards, federal	$ 860
Tax credit carryforwards, state	$ 905
Research Tax Credit Carryforward [Member] | Minimum [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards, expiration date, federal	Dec. 31, 2030
Research Tax Credit Carryforward [Member] | Maximum [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards, expiration date, federal	Dec. 31, 2036
BioTime, Inc. [Member]
Class of Stock [Line Items]
Company share in market transactions (in shares)		259,712
Investors taxable gain		$ 815
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 30,600
Federal [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2030
Federal [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2036
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 15,100
State [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2029
State [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2036

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Apr. 07, 2016	Dec. 31, 2016
Shared Facilities and Service Agreement [Abstract]
Minimum fixed payments due under the shared facilities agreement		$ 15,000
Commitments and Contingencies [Abstract]
Lease agreement value		626,000
Employment Contracts [Abstract]
Potential severance obligations for termination without cause		420,000
Potential severance obligations for termination due to change in control		624,000
Master Lease Line Agreement [Member]
Commitments and Contingencies [Abstract]
Lease agreement value	$ 458,000	168,000
Fair value of equipment at inception		$ 626,000
Capital lease term		36 months
Interest rate on lease agreement	10.00%
Percentage of restocking fee paid on original cost of equipment	7.50%
Monthly payment under capital lease	$ 14,442	$ 5,342
Available amount under lease agreement		$ 249,000
Minimum [Member] | Master Lease Line Agreement [Member]
Commitments and Contingencies [Abstract]
Increment value of lease agreement	$ 50,000
Percentage of fair value on original cost to purchase an equipment	12.50%
Maximum [Member] | Master Lease Line Agreement [Member]
Commitments and Contingencies [Abstract]
Lease agreement value	$ 875,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Feb. 21, 2017	Feb. 17, 2017	Aug. 29, 2016	Dec. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Warrant exercise price (in dollars per share)				$ 3.25
Warrants exercise cash proceeds			$ 9,800,000
Warrants exercisable term				5 years
Ownership percentage			51.20%
BioTime, Inc. [Member]
Subsequent Event [Line Items]
Ownership percentage				51.10%	57.70%
Subsequent Event [Member]
Subsequent Event [Line Items]
Warrants exercised (in shares)		625,000
Warrant exercise price (in dollars per share)		$ 3.25
Warrants exercise cash proceeds		$ 2,000,000
Warrants exercisable term		5 years
Warrants outstanding (in shares)		3,033,653
Subsequent Event [Member] | BioTime, Inc. [Member]
Subsequent Event [Line Items]
Warrants exercised (in shares)		625,000
Warrant exercise price (in dollars per share)		$ 3.25
Warrants exercise cash proceeds		$ 2,000,000
Ownership percentage		50.00%
Subsequent Event [Member] | Maximum [Member] | BioTime, Inc. [Member]
Subsequent Event [Line Items]
Ownership percentage		50.00%
Subsequent Event [Member] | Employees [Member]
Subsequent Event [Line Items]
Stock options granted (in shares)		357,130
Stock options exercise price (in dollars per share)		$ 4.70
Subsequent Event [Member] | Investors Group 1 [Member]
Subsequent Event [Line Items]
Warrant exercise price (in dollars per share)		$ 5.50
Warrants issued (in shares)		200,000
Subsequent Event [Member] | Investors Group 2 [Member]
Subsequent Event [Line Items]
Warrant exercise price (in dollars per share)		$ 3.25
Warrants issued (in shares)		212,500
Subsequent Event [Member] | Silicon Valley Bank [Member]
Subsequent Event [Line Items]
Warrant exercise price (in dollars per share)	$ 4.85
Warrants issued (in shares)	8,247
Secured credit facility	$ 2,000,000
Amount by which credit line can be increased	3,000,000
Additional equity capital	$ 20,000,000
Basis spread variable rate	0.75%
Base rate	4.25%
Stated floating annual interest rate	4.50%
Additional final payment fee percentage	5.80%
Prepayment fee if prepaid within one year	3.00%
Prepayment fee if prepaid more than one year but less than two years	2.00%
Prepayment fee if prepaid two years or more	1.00%
Additional shares of common stock issuable upon the exercise	2.00%
Subsequent Event [Member] | Silicon Valley Bank [Member] | Minimum [Member]
Subsequent Event [Line Items]
Penalty amount in event of default	$ 50,000